Agios Pharmaceuticals, Inc. (AGIO) is an innovative biopharmaceutical company established in 2008 that is advancing the field of cellular metabolism to treat cancer and rare genetic diseases. The American company is headquartered in Cambridge, Massachusetts, and is publicly traded and listed on the NASDAQ Stock Market.
The vision that drives Agios is to fundamentally change the way patients feel from devastating diseases by harnessing the power of cellular metabolism. The company's dedication to this vision has allowed it to express unique leadership in the field of cellular metabolism, enabling Agios to continually break boundaries with their research and therapeutics.
Agios has a robust pipeline of novel investigational medicines aimed at providing cutting-edge solutions for patients in areas where limited or no therapeutic options exist. Their focus on cancer involves developing therapies that have the ability to target and halt cancer cells' metabolic activities, thereby inhibiting their growth and proliferation. In the realm of rare genetic diseases, Agios is dedicated to understanding the root cause, as they occur due to mutations that affect the metabolism of certain cells.
Tibsovo® is one of Agios’ main products. It is the first and only FDA-approved therapy that targets the IDH1 mutation, commonly found in many types of cancer including Leukemia. In addition to Tibsovo®, Agios' portfolio includes a number of clinical-stage and investigational medicines such as Mitapivat for Pyruvate Kinase deficiency and Vorasidenib for IDH-mutant low-grade glioma, amongst others.
Agios' approach to medical discovery and development relies heavily on collaboration, which they engage in through partnerships with several other innovative companies and academic institutions. They conserve a multidisciplinary team of dedicated professionals who tackle the most complex health issues with scientific rigor and a spirit of innovation.
To fund its operations and research, Agios Pharmaceuticals, Inc. generates revenues mainly from product sales, collaboration agreements, and government funding. Throughout the years, Agios has faced challenges, but their commitment to research, innovation, and patient care has allowed them to remain at the forefront of their field. They continue to make strides in the biopharmaceutical sector through their ground-breaking research and development activities in the realm of cellular metabolism.
Ultimately, Agios Pharmaceuticals, Inc. is a pioneering company striving to translational medicine as they continue to push the boundaries in drug discovery and development, bringing new hope to patients through their novel, metabolism-based therapies. The journey of Agios Pharmaceuticals symbolizes the possible nexus between advancing science, commitment to patients, and commercial success.